{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:25:37Z","timestamp":1782491137132,"version":"3.54.5"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Critically ill children are at risk for subtherapeutic antibiotic concentrations. The frequency of target attainment and risk factors for subtherapeutic concentrations of cefepime in children have not been extensively studied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      We performed an observational study in critically ill children receiving a new prescription of standard dosing of cefepime for suspected sepsis (\u22652 systemic inflammatory response syndrome criteria within 48 hours of cefepime start). Three plasma cefepime concentrations were measured at steady state and, a urine sample was collected prior to pharmacokinetics (PK) sampling for measurement of urinary biomarkers. Bayesian analysis determined cefepime PK for each individual, and simulations were used to estimate time above minimum inhibitory concentration (\n                      <jats:italic toggle=\"yes\">f<\/jats:italic>\n                      T &gt; MIC) for 8 \u00b5g\/mL (breakpoint for\n                      <jats:italic toggle=\"yes\">Pseudomonas<\/jats:italic>\n                      ). Clinical factors and urinary biomarkers were compared between patients who did and did not achieve 100%\n                      <jats:italic toggle=\"yes\">f<\/jats:italic>\n                      T &gt; MIC. Correlations between covariates and cefepime PK parameters, as well as optimal cut points to identify &lt;100%\n                      <jats:italic toggle=\"yes\">f<\/jats:italic>\n                      T &gt; MIC, were evaluated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Twenty-one subjects were enrolled and PK sampling occurred after a median of 5 doses (range, 3\u20139); 43% of children achieved 100%\n                      <jats:italic toggle=\"yes\">f<\/jats:italic>\n                      T &gt; MIC for an MIC of 8 \u00b5g\/mL. Younger age and lower urinary biomarkers (neutrophil gelatinase-associated lipocalin and kidney injury molecule-1) were significantly associated with failure to attain 100%\n                      <jats:italic toggle=\"yes\">f<\/jats:italic>\n                      T &gt; 8 \u00b5g\/mL. Urinary neutrophil gelatinase-associated lipocalin (&lt;122.1-ng\/mg creatinine) best identified individuals who failed to attain this putative target (positive predictive value, 91.7%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      A large proportion of critically ill children failed to attain target concentrations for empiric treatment of\n                      <jats:italic toggle=\"yes\">Pseudomonas aeruginosa<\/jats:italic>\n                      with cefepime. Urinary biomarkers may be a noninvasive means to identify those at higher risk for increased cefepime clearance and subtherapeutic concentrations.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000004784","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T17:01:28Z","timestamp":1741798888000},"page":"749-754","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Urinary Biomarkers and Attainment of Cefepime Therapeutic Targets in Critically Ill Children"],"prefix":"10.1097","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5015-8146","authenticated-orcid":false,"given":"Kevin J.","family":"Downes","sequence":"first","affiliation":[{"name":"Department of Pediatrics"},{"name":"Division of Infectious Diseases"},{"name":"Center for Clinical Pharmacology"},{"name":"Clinical Futures"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sharova","sequence":"additional","affiliation":[{"name":"Center for Clinical Pharmacology"},{"name":"Clinical Futures"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Amajor","sequence":"additional","affiliation":[{"name":"Center for Clinical Pharmacology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Gianchetti","sequence":"additional","affiliation":[{"name":"Clinical Futures"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Himebauch","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Critical Care, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA"},{"name":"Division of Critical Care Medicine, Children\u2019s Hospital of Philadelphia, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie C.","family":"Fitzgerald","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Critical Care, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA"},{"name":"Clinical Futures"},{"name":"Division of Critical Care Medicine, Children\u2019s Hospital of Philadelphia, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athena F.","family":"Zuppa","sequence":"additional","affiliation":[{"name":"Department of Pediatrics"},{"name":"Center for Clinical Pharmacology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,7]]},"reference":[{"key":"R1-20250723","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ijantimicag.2011.11.002","article-title":"How to optimise antimicrobial prescriptions in the intensive care unit: principles of individualised dosing using pharmacokinetics and pharmacodynamics.","volume":"39","author":"Roberts","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"R2-20250723","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/2110-5820-2-35","article-title":"Does beta-lactam pharmacokinetic variability in critically Ill patients justify therapeutic drug monitoring? A systematic review.","volume":"2","author":"Sime","year":"2012","journal-title":"Ann Intensive Care"},{"key":"R3-20250723","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R4-20250723","doi-asserted-by":"crossref","first-page":"R126","DOI":"10.1186\/cc9091","article-title":"Insufficient beta-lactam concentrations in the early phase of severe sepsis and septic shock.","volume":"14","author":"Taccone","year":"2010","journal-title":"Crit Care"},{"key":"R5-20250723","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40262-019-00813-w","article-title":"Pharmacokinetics and target attainment of antibiotics in critically ill children: a systematic review of current literature.","volume":"59","author":"Hartman","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"R6-20250723","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1093\/jac\/dkaa363","article-title":"beta-Lactam antimicrobial pharmacokinetics and target attainment in critically ill patients aged 1 day to 90 years: the ABDose study.","volume":"75","author":"Lonsdale","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"R7-20250723","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1128\/AAC.02592-15","article-title":"Population pharmacokinetic assessment and pharmacodynamic implications of pediatric cefepime dosing for susceptible-dose-dependent organisms.","volume":"60","author":"Shoji","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"R8-20250723","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/PCC.0000000000001502","article-title":"Hospital variation in risk-adjusted pediatric sepsis mortality.","volume":"19","author":"Ames","year":"2018","journal-title":"Pediatr Crit Care Med"},{"key":"R9-20250723","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1001\/jamapediatrics.2018.4839","article-title":"Global case-fatality rates in pediatric severe sepsis and septic shock: a systematic review and meta-analysis.","volume":"173","author":"Tan","year":"2019","journal-title":"JAMA Pediatr"},{"key":"R10-20250723","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1164\/rccm.201412-2323OC","article-title":"Global epidemiology of pediatric severe sepsis: the sepsis prevalence, outcomes, and therapies study.","volume":"191","author":"Weiss","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"R11-20250723","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1097\/CCM.0000000000000509","article-title":"Delayed antimicrobial therapy increases mortality and organ dysfunction duration in pediatric sepsis.","volume":"42","author":"Weiss","year":"2014","journal-title":"Crit Care Med"},{"key":"R12-20250723","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ijantimicag.2007.12.009","article-title":"Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.","volume":"31","author":"McKinnon","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"R13-20250723","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper.","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"R14-20250723","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1093\/jac\/dkx001","article-title":"Determining beta-lactam exposure threshold to suppress resistance development in Gram-negative bacteria.","volume":"72","author":"Tam","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"R15-20250723","doi-asserted-by":"crossref","first-page":"106443","DOI":"10.1016\/j.ijantimicag.2021.106443","article-title":"Assessment of cefepime toxicodynamics: comprehensive examination of pharmacokinetic\/pharmacodynamic targets for cefepime-induced neurotoxicity and evaluation of current dosing guidelines.","volume":"58","author":"Lau","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"R16-20250723","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.2215\/CJN.01640309","article-title":"Measurement and estimation of GFR in children and adolescents.","volume":"4","author":"Schwartz","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R17-20250723","doi-asserted-by":"crossref","first-page":"5742","DOI":"10.1128\/AAC.00591-16","article-title":"Evaluation of vancomycin exposures associated with elevations in novel urinary biomarkers of acute kidney injury in vancomycin-treated rats.","volume":"60","author":"Rhodes","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"R18-20250723","doi-asserted-by":"crossref","first-page":"c154","DOI":"10.1159\/000312879","article-title":"Predicting cisplatin-induced acute kidney injury by urinary neutrophil gelatinase-associated lipocalin excretion: a pilot prospective case-control study. Comparative study.","volume":"115","author":"Gaspari","year":"2010","journal-title":"Nephron Clin Pract"},{"key":"R19-20250723","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/jac\/dkw351","article-title":"Urinary kidney injury biomarkers and tobramycin clearance among children and young adults with cystic fibrosis: a population pharmacokinetic analysis.","volume":"72","author":"Downes","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"R20-20250723","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/01.PCC.0000149131.72248.E6","article-title":"Members of the International Consensus Conference on Pediatric Sepsis. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics.","volume":"6","author":"Goldstein","year":"2005","journal-title":"Pediatr Crit Care Med"},{"key":"R21-20250723","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/PCC.0000000000001786","article-title":"A population pharmacokinetic analysis to study the effect of extracorporeal membrane oxygenation on cefepime disposition in children.","volume":"20","author":"Zuppa","year":"2019","journal-title":"Pediatr Crit Care Med"},{"key":"R22-20250723","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD.","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R23-20250723","doi-asserted-by":"crossref","first-page":"1389.e1","DOI":"10.1016\/j.cmi.2022.05.007","article-title":"Cefepime population pharmacokinetics and dosing regimen optimization in critically ill children with different renal function.","volume":"28","author":"de Cacqueray","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"R24-20250723","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1128\/AAC.41.8.1783","article-title":"Pharmacokinetics of intravenously and intramuscularly administered cefepime in infants and children.","volume":"41","author":"Reed","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"R25-20250723","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00745-20","article-title":"Population pharmacokinetics and target attainment of cefepime in critically ill patients and guidance for initial dosing.","volume":"64","author":"Al-Shaer","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R26-20250723","doi-asserted-by":"crossref","first-page":"614.e1","DOI":"10.1016\/j.jtct.2024.03.021","article-title":"Cystatin C outperforms creatinine in predicting cefepime clearance in pediatric stem cell transplant recipients.","volume":"30","author":"Hambrick","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"R27-20250723","first-page":"e0446","article-title":"Setting the beta-lactam therapeutic range for critically ill patients: is there a floor or even a ceiling?","volume":"3","author":"Barreto","year":"2021","journal-title":"Crit Care Explor"},{"key":"R28-20250723","doi-asserted-by":"crossref","first-page":"e1021","DOI":"10.1093\/cid\/ciac698","article-title":"Antibiotic indications and appropriateness in the pediatric intensive care unit: a 10-center point prevalence study.","volume":"76","author":"Chiotos","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"4S","key":"R29-20250723","first-page":"S117","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"2","key":"R30-20250723","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00467-024-06477-4","article-title":"Acute kidney injury is associated with abnormal cefepime exposure among critically ill children and young adults.","volume":"40","author":"Pavia","year":"2025","journal-title":"Pediatr Nephrol"},{"key":"R31-20250723","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1515\/jpem-2020-0138","article-title":"Role of urinary NGAL and KIM-1 as biomarkers of early kidney injury in obese prepubertal children.","volume":"33","author":"Polidori","year":"2020","journal-title":"J Pediatr Endocrinol Metab"},{"key":"R32-20250723","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s12519-017-0110-x","article-title":"Urinary neutrophil gelatinase-associated lipocalin (NGAL) and serum cystatin C measurements for early diagnosis of acute kidney injury in children admitted to PICU.","volume":"14","author":"Kari","year":"2018","journal-title":"World J Pediatr"},{"key":"R33-20250723","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/FTD.0000000000000496","article-title":"Acute kidney injury biomarkers predict an increase in serum milrinone concentration earlier than serum creatinine-defined acute kidney injury in infants after cardiac surgery.","volume":"40","author":"Gist","year":"2018","journal-title":"Ther Drug Monit"},{"key":"R34-20250723","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.3390\/pharmaceutics15051336","article-title":"Optimizing vancomycin therapy in critically ill children: a population pharmacokinetics study to inform vancomycin area under the curve estimation using novel biomarkers.","volume":"15","author":"Downes","year":"2023","journal-title":"Pharmaceutics"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004784","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T20:00:29Z","timestamp":1753300829000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004784","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.12.30.21268328","asserted-by":"object"}]},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,7]]}}}